Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3312 plus sotorasib in advanced solid tumors
2022-003564-24Phase 2Terminated
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Jan 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitneprotafib and sotorasib in Nonhematologic neoplasms, sponsored by Jacobio Pharmaceuticals. Primary endpoint: Objective response rate. Started Jan 2024; status: terminated.
02
Drugs
sitneprotafibsotorasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-003564-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003564-24.